基于超声和MRI病灶可见性的前列腺癌检出率
该研究纳入2016至2017年间接受经直肠超声引导前列腺活检的1022例患者,按活检前是否行MRI及MRI上病灶是否可见分为三组,比较经直肠超声可见与不可见病灶患者间的活检结果。经直肠超声和MRI可见的前列腺局灶性病灶均与临床显著前列腺癌的检出显著相关。
要点
- 经直肠超声可见病灶者临床显著癌检出率39.4%,不可见者13.1%,差异有统计学意义。
- MRI和经直肠超声的病灶可见性均与临床显著前列腺癌检出正相关。
- 无活检前MRI患者中,经直肠超声可见病灶者癌检出率亦显著更高。
核心结论
- 前列腺内经直肠超声和MRI可见的局灶性病灶与临床显著前列腺癌的检出显著相关。
研究设计与样本
- 研究纳入2016至2017年接受经直肠超声引导前列腺活检的患者1022例,分为未行活检前MRI组(622例)、MRI无可见病灶组(77例)和MRI有可见病灶组(323例),比较活检结果。
关键影像表现/征象
- 经直肠超声可见局灶性病灶的患者共710例。
- 经直肠超声可见病灶者临床显著癌检出率为39.4%,不可见者为13.1%,差异有统计学意义(p<0.001)。
诊断标准与关键数值
- 经直肠超声可见病灶者临床显著癌检出率39.4%,不可见者13.1%(p<0.001)。
- MRI可见病灶与临床显著癌检出相关(p=0.002),经直肠超声可见病灶亦相关(p<0.001)。
- 未行活检前MRI组和MRI有可见病灶组中,经直肠超声可见病灶者癌检出率显著更高(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To evaluate the difference in prostate cancer detection rates according to lesion visibility using transrectal ultrasound (TRUS) and magnetic resonance imaging (MRI) before biopsy.
MATERIALS AND METHODS: Patients who underwent TRUS-guided prostate biopsy in 2016 and 2017 (n=1,022) were divided into three groups: (1) patients who did not undergo a prebiopsy MRI (group 1, n=622); (2) patients without visible lesions on the prebiopsy MRI (group 2, n=77); and (3) patients with visible lesions on the prebiopsy MRI (group 3, n=323). Biopsy results were compared using chi-square tests or independent t-tests between patients with and without TRUS-visible lesions in each group. A logistic regression test was used to determine the variables independently associated with the detection of clinically significant cancer.
RESULTS: Focal lesions were visible on TRUS in 710 patients. Clinically significant cancers were detected in 39.4% and 13.1% of patients with and without TRUS-visible lesions, respectively (p<0.001). The cancer detection rate was significantly higher in patients with TRUS-visible lesions in groups 1 and 3 (p<0.001). Within group 1, the Gleason scores, number of positive cores, and the cancer involvement ratios were significantly greater in patients with TRUS-visible lesions than in patients without TRUS-visible lesions. MRI- and TRUS visibility were positively associated with the detection of clinically significant prostate cancer (p=0.002 and p<0.001, respectively).
CONCLUSION: TRUS- and MRI-visible focal lesions in the prostate were significantly associated with the detection of clinically significant cancer.
引用
- Choi MH, Lee YJ, Jung SE, et al. Prostate cancer detection rate according to lesion visibility using ultrasound and MRI. Clin Radiol. 2019. PMID: 30846191. doi:10.1016/j.crad.2019.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。